Stock listing
NASDAQ:ALXO ALX Oncology Holdings Inc. Stock
Home listing (NASDAQ) of ALX Oncology Holdings Inc.
Follow ALX Oncology Holdings Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ALXO
$1.16 USD +0.01 (+0.4%)
Close on Nov 6, 2026
- Day range
- $1.03 – $1.17 USDNov 6, 2026
- Volume
- 918,433 sharesNov 6, 2026
- Market cap
- $159.7M USDAt the close on Nov 6, 2026 · price × 138.3M shares outstanding
- 52-week range
- $0.862 – $2.66 USDLowest and highest trades, Nov 7, 2025 – Nov 6, 2026
- Traded on an average day
- $1.94M USDMedian day 909,877 shares · last 3 months, Aug 6, 2026 – Nov 6, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ALXO · Home | $1.155 USD | +0.005 (+0.4%) | 918,433 | $1.16 | $1.165 | $1.03 | $1.15 | Close on Nov 6, 2026 |
Daily closes
Last 3 months, Aug 6, 2026 – Nov 6, 2026 · NASDAQ:ALXO · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.155 | +0.005 | +0.4% | $1.16 | $1.165 | $1.03 | 918,433 | |
| $1.15 | -0.21 | -15.4% | $1.37 | $1.37 | $1.12 | 797,100 | |
| $1.36 | +0.07 | +5.4% | $1.32 | $1.40 | $1.32 | 949,515 | |
| $1.29 | -0.08 | -5.8% | $1.38 | $1.38 | $1.265 | 728,990 | |
| $1.37 | +0.15 | +12.3% | $1.23 | $1.42 | $1.20 | 1,610,245 | |
| $1.22 | 0.00 | 0.0% | $1.20 | $1.26 | $1.195 | 422,202 | |
| $1.22 | +0.04 | +3.4% | $1.21 | $1.34 | $1.12 | 1,532,604 | |
| $1.18 | +0.08 | +7.3% | $1.09 | $1.19 | $1.03 | 2,946,276 | |
| $1.10 | -0.03 | -2.7% | $1.14 | $1.175 | $1.045 | 3,215,733 | |
| $1.13 | -0.04 | -3.4% | $1.19 | $1.19 | $1.09 | 1,037,527 | |
| $1.17 | -0.02 | -1.7% | $1.17 | $1.23 | $1.10 | 556,386 | |
| $1.19 | +0.04 | +3.5% | $1.15 | $1.20 | $1.141 | 572,813 | |
| $1.15 | -0.09 | -7.3% | $1.25 | $1.30 | $1.15 | 934,510 | |
| $1.24 | +0.10 | +8.8% | $1.125 | $1.27 | $1.11 | 871,501 | |
| $1.14 | +0.08 | +7.5% | $1.05 | $1.145 | $1.015 | 1,013,476 | |
| $1.06 | +0.06 | +6.0% | $1.00 | $1.155 | $0.931 | 2,429,527 | |
| $1.00 | +0.105 | +11.8% | $0.911 | $1.02 | $0.862 | 3,709,989 | |
| $0.895 | -0.085 | -8.7% | $0.99 | $0.99 | $0.886 | 2,569,087 | |
| $0.98 | -0.28 | -22.3% | $1.26 | $1.26 | $0.979 | 1,002,715 | |
| $1.26 | +0.01 | +0.8% | $1.21 | $1.27 | $1.185 | 894,803 | |
| $1.25 | +0.07 | +5.9% | $1.16 | $1.29 | $1.151 | 1,224,926 | |
| $1.18 | +0.05 | +4.4% | $1.13 | $1.20 | $1.08 | 1,806,000 | |
| $1.13 | +0.02 | +1.8% | $1.11 | $1.15 | $1.10 | 764,262 | |
| $1.11 | -0.10 | -8.3% | $1.19 | $1.21 | $1.09 | 1,014,121 | |
| $1.21 | -0.01 | -0.8% | $1.22 | $1.27 | $1.14 | 1,788,732 | |
| $1.22 | -0.08 | -6.2% | $1.30 | $1.379 | $1.205 | 2,256,846 | |
| $1.30 | -0.09 | -6.5% | $1.37 | $1.42 | $1.28 | 1,481,501 | |
| $1.39 | +0.04 | +3.0% | $1.34 | $1.46 | $1.31 | 1,344,372 | |
| $1.35 | -0.04 | -2.9% | $1.37 | $1.445 | $1.325 | 1,775,584 | |
| $1.39 | +0.08 | +6.1% | $1.32 | $1.445 | $1.30 | 1,959,125 | |
| $1.31 | -0.045 | -3.3% | $1.34 | $1.37 | $1.29 | 1,168,041 | |
| $1.355 | -0.115 | -7.8% | $1.46 | $1.49 | $1.34 | 1,204,594 | |
| $1.47 | -0.13 | -8.1% | $1.59 | $1.60 | $1.43 | 1,277,330 | |
| $1.60 | -0.06 | -3.6% | $1.68 | $1.68 | $1.60 | 652,788 | |
| $1.66 | -0.04 | -2.4% | $1.72 | $1.72 | $1.65 | 849,657 | |
| $1.70 | -0.04 | -2.3% | $1.74 | $1.75 | $1.67 | 5,063,199 | |
| $1.74 | -0.02 | -1.1% | $1.79 | $1.80 | $1.735 | 526,481 | |
| $1.76 | -0.13 | -6.9% | $1.90 | $1.91 | $1.74 | 821,212 | |
| $1.89 | -0.035 | -1.8% | $1.92 | $1.92 | $1.86 | 758,972 | |
| $1.925 | -0.015 | -0.8% | $1.98 | $1.98 | $1.915 | 879,740 | |
| $1.94 | +0.04 | +2.1% | $1.91 | $2.005 | $1.85 | 1,036,362 | |
| $1.90 | +0.06 | +3.3% | $1.85 | $1.925 | $1.81 | 1,061,557 | |
| $1.84 | -0.16 | -8.0% | $1.97 | $2.02 | $1.84 | 770,489 | |
| $2.00 | -0.01 | -0.5% | $1.97 | $2.02 | $1.96 | 425,515 | |
| $2.01 | -0.02 | -1.0% | $2.00 | $2.03 | $1.99 | 301,115 | |
| $2.03 | -0.05 | -2.4% | $2.09 | $2.09 | $1.995 | 603,424 | |
| $2.08 | +0.10 | +5.1% | $1.98 | $2.09 | $1.98 | 855,107 | |
| $1.98 | +0.05 | +2.6% | $1.91 | $2.00 | $1.895 | 1,441,610 | |
| $1.93 | -0.07 | -3.5% | $2.07 | $2.07 | $1.895 | 349,438 | |
| $2.00 | -0.05 | -2.4% | $2.02 | $2.04 | $1.98 | 639,792 | |
| $2.05 | +0.07 | +3.5% | $1.97 | $2.055 | $1.965 | 628,152 | |
| $1.98 | -0.02 | -1.0% | $1.98 | $2.005 | $1.95 | 385,052 | |
| $2.00 | +0.01 | +0.5% | $1.98 | $2.045 | $1.98 | 466,069 | |
| $1.99 | -0.05 | -2.5% | $2.02 | $2.03 | $1.95 | 273,463 | |
| $2.04 | +0.05 | +2.5% | $2.01 | $2.07 | $1.98 | 410,888 | |
| $1.99 | -0.07 | -3.4% | $2.05 | $2.061 | $1.97 | 473,673 | |
| $2.06 | -0.02 | -1.0% | $2.10 | $2.135 | $2.025 | 1,221,858 | |
| $2.08 | +0.11 | +5.6% | $1.95 | $2.08 | $1.94 | 901,321 | |
| $1.97 | +0.01 | +0.5% | $1.93 | $2.00 | $1.905 | 698,702 | |
| $1.96 | +0.02 | +1.0% | $1.95 | $2.00 | $1.92 | 584,160 | |
| $1.94 | -0.07 | -3.5% | $2.01 | $2.02 | $1.935 | 953,663 | |
| $2.01 | +0.08 | +4.1% | $1.91 | $2.02 | $1.90 | 2,419,813 | |
| $1.93 | -0.13 | -6.3% | $2.09 | $2.09 | $1.90 | 620,475 | |
| $2.06 | -0.04 | -1.9% | $2.10 | $2.135 | $2.031 | 506,207 | |
| $2.10 | -0.01 | -0.5% | $2.13 | $2.18 | $2.04 | 8,493,579 | |
| $2.11 | +0.19 | +9.9% | $1.94 | $2.14 | $1.87 | 580,906 |
- Ticker
- NASDAQ:ALXO
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Sep 28, 2026
ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
Latest earnings call · May 8, 2026
ALX Oncology Holdings (NASDAQ:ALXO) Q1 2026 Earnings Call
Replay and transcript
Latest deck · August 2026
Investor Presentation (August 2026)
Investor deck · 36 slides
Calls
Replays
ALX Oncology Holdings (NASDAQ:ALXO) Q1 2026 Earnings Call
Fri, May 08, 2026 · 8:30 AM ET
Watch TranscriptALX Oncology Holdings (NASDAQ:ALXO) Q4 2025 Earnings Call
Fri, Feb 27, 2026 · 8:30 AM ET
Watch TranscriptALX Oncology Holdings (NASDAQ:ALXO) Q3 2025 Earnings Call
Fri, Nov 07, 2025 · 8:30 AM ET
Watch Transcript
Latest news
ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
Sep 28, 2026
Closed $1.39 (+6.1%) on Sep 28, 2026
ALX Oncology to Present at Upcoming Investor Conferences in September
Sep 2, 2026
Closed $2.08 (+5.1%) on Sep 2, 2026
ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Aug 6, 2026
Closed $2.11 (+9.9%) on Aug 6, 2026
ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel
Jun 30, 2026
Closed $2.07 (-5.9%) on Jun 30, 2026
ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York
Jun 1, 2026
Closed $1.80 (-5.3%) on Jun 1, 2026
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 8, 2026
Closed $2.08 (+11.2%) on May 8, 2026
ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026
Apr 30, 2026
Closed $1.70 (+7.6%) on Apr 30, 2026
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
Apr 17, 2026
Closed $1.75 (+4.8%) on Apr 20, 2026
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer
Apr 13, 2026
Closed $1.75 (+2.9%) on Apr 13, 2026
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Mar 2, 2026
Closed $2.12 (+0.5%) on Mar 2, 2026
Financings
Public offering of common stock and pre-funded warrants
Jan 30, 2026
Announced: about US$150M · US$1.57 a share · Piper Sandler +2
Dealers: Piper Sandler (co-lead), UBS Investment Bank (co-lead), Wells Fargo Securities (co-lead)
Buyers: RA Capital Management; TCGX; 5AM Ventures; Blackstone Multi-Asset Investing; Coastlands Capital; Driehaus Capital Management; HBM Healthcare Investments; Marshall Wace; OrbiMed; Redmile Group; venBio Partners; Vivo Capital
Use of proceeds: Clinical development of evorpacept and ALX2004 and related trials, plus working capital and general corporate purposes
Decks
Investor Presentation (August 2026)
Investor deck · 36 slides · August 2026
Q1 2026 Earnings Presentation
Earnings · 38 slides · May 8, 2026
Q4 2025 Earnings Presentation
Earnings · 37 slides · Feb 27, 2026
Q3 2025 Earnings Presentation
Earnings · 39 slides · Nov 7, 2025
ALX Oncology Holdings Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 19 in the last 12 months · 137 in all · newest Sep 28, 2026 · oldest 2020
- Calls
- 4 calls with a replay · 4 with a transcript · latest May 8, 2026
- Decks
- 8 decks · latest August 2026
Where ALX Oncology Holdings Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ALXO · Home listing · This page | NASDAQ | United States | USD |
| BOATS:ALXO | BOATS | United States | USD |
Log in to ask 6ix AI your own questions about ALX Oncology Holdings Inc.